Amandeep Sandhu, MD
Allergy · Marlton, NJNPI 1174977227
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,729 of the $8,643 with a category attached, or 89.4%. It is spread thinly across 33 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations.
Across 405 payments — averaging $21.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$2K
- GSK$1K
- AstraZeneca$1K
- Amgen$626
- Regeneron Healthcare Solutions, Inc.$617
- Pfizer$497
- plus $2K from 27 others
What the payments were for
- Grants$7008%
- Food & beverage$7,72989%
- Education$2142%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 43 | $1,916 |
| GSK | 104 | $1,351 |
| AstraZeneca | 40 | $1,334 |
| Amgen(2 entities) | 24 | $626 |
| Regeneron Healthcare Solutions, Inc. | 23 | $617 |
| Pfizer | 58 | $497 |
| CSL Behring | 19 | $342 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $268 |
| Grifols USA, LLC | 7 | $240 |
| Kaleo, Inc. | 15 | $232 |
| Novartis | 8 | $153 |
| Sanofi-aventis U.S. LLC | 2 | $134 |
| Optinose US, Inc. | 8 | $123 |
| Genentech USA, Inc. | 7 | $118 |
| Pharming Healthcare, Inc. | 1 | $108 |
| Shire North American Group Inc | 1 | $101 |
| ARS Pharmaceuticals Operations, Inc. | 5 | $88 |
| Biocryst US Sales Co., LLC | 4 | $70 |
| Hikma Pharmaceuticals USA | 3 | $43 |
| Ionis Pharmaceuticals, Inc. | 2 | $36 |
| LEO Pharma Inc. | 2 | $30 |
| AbbVie | 2 | $27 |
| GC Biopharma USA, Inc. | 1 | $25 |
| Abbott | 1 | $20 |
| Phadia US Inc. | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Covis Pharma GmbH | 1 | $18 |
| Octapharma USA, Inc. | 1 | $16 |
| Merck | 1 | $16 |
| Kedrion Biopharma, Inc. | 1 | $15 |
| Bio Products Laboratory USA, Inc. | 1 | $15 |
| Organon | 2 | $15 |
| Philips North America LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,643 in reported general payments places this provider in the 65th percentile of 35 allergy providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 13 | $97,738 |
| Dupixent SyringeDupilumab | 19 | $67,929 |
| Dupixent PenDupilumab | 14 | $48,681 |
| XolairOmalizumab | 11 | $47,070 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $42,151 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 28 | $10,046 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $5,597 |
| Epinephrine | 12 | $2,478 |
| Montelukast Sodium | 98 | $1,746 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 31 | $1,466 |
| Azelastine Hcl | 20 | $681 |
| Fluticasone Propionate | 30 | $580 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $104 |
| Prednisone | 25 | $58 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPanzyga | $497 | $97,73813 claims |
| GSKTrelegy Ellipta | $1,351 | $42,15132 claims |
| AstraZenecaSymbicort | $1,334 | $5,59714 claims |
| Hikma Pharmaceuticals USAEpinephrine | $43 | $2,47812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 35 allergy providers in New Jersey.
Other allergy in Marlton
- Gregory TociMarlton$317K
- Eugene GattiMarlton$43K
- John OppenheimerCedar Knolls$922K
- Jeffrey WeissRiverdale$532K
- Jay KashkinFair Lawn$436K
- Howard DruceSomerville$37K
- Shashank ShethVoorhees$33K
- Donatella GraffinoCedar Knolls$15K
- Maria Lania-HowarthVoorhees$12K
- Jamie ZachariasSewell$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.